Novo Nordisk A/S (NYSE:NVO) shares saw strong trading volume on Monday . 4,235,029 shares traded hands during mid-day trading, an increase of 43% from the previous session’s volume of 2,964,876 shares.The stock last traded at $46.81 and had previously closed at $46.18.

A number of analysts recently weighed in on the stock. Citigroup Inc. reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Wednesday, August 3rd. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $63.00 price objective on the stock in a report on Tuesday, May 3rd. Goldman Sachs Group Inc. cut shares of Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. Finally, Bank of America Corp. cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Monday, August 8th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $61.00.

The company’s 50-day moving average is $53.33 and its 200-day moving average is $53.91. The company has a market cap of $119.14 billion and a PE ratio of 22.127.

The business also recently disclosed a dividend, which will be paid on Tuesday, August 23rd. Stockholders of record on Monday, August 15th will be paid a $0.326 dividend. The ex-dividend date is Thursday, August 11th.

A hedge fund recently raised its stake in Novo Nordisk A/S stock. Bank of Montreal Can increased its stake in Novo Nordisk A/S (NYSE:NVO) by 16.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 64,142 shares of the company’s stock after buying an additional 8,892 shares during the period. Bank of Montreal Can’s holdings in Novo Nordisk A/S were worth $3,726,000 at the end of the most recent reporting period.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.